4.7 Article

GATA6 suppresses migration and metastasis by regulating the miR-520b/CREB1 axis in gastric cancer

Journal

CELL DEATH & DISEASE
Volume 10, Issue -, Pages -

Publisher

SPRINGERNATURE
DOI: 10.1038/s41419-018-1270-x

Keywords

-

Categories

Funding

  1. National Key R&D Program of China [2018YFC1313101]
  2. National Natural Science Foundation of China [81430072, 81602641, 81822031, 81871913, 81572929]
  3. Young Elite Scientists Sponsorship Program by CAST [2017QNRC001]
  4. China Postdoctoral Science Foundation
  5. Open Funding of Key Laboratory of Resource Biology and Biotechnology in Northwest University [ZSK2017010]

Ask authors/readers for more resources

Transcription factors (TFs) and microRNAs (miRNAs) are tightly linked to each other in tumor development and progression, but their interactions in gastric cancer (GC) metastasis remain elusive. Here we report a novel suppressive role of GATA6 in inhibiting GC metastasis by transactivating miR-520b. We found that GATA6 expression was significantly downregulated in metastatic GC cells and tissues and that its downregulation was correlated with a poor GC prognosis. Overexpression of GATA6 suppressed GC cell migration, invasion and metastasis both in vitro and in vivo. Luciferase reporter assays and chromatin immunoprecipitation assays demonstrated that miR-520b is a direct transcriptional target of GATA6. Moreover, miR-520b expression was positively correlated with GATA6 expression in GC tissues, and ectopic expression of miR-520b inhibited the migration and invasion of GC cells. Furthermore, cAMP responsive element binding protein 1 (CREB1) was identified as a direct and functional target of miR-520b, and GATA6 could suppress GC cell migration and metastasis via miR-520b-mediated repression of CREB1. Downregulation of GATA6 and miR-520b may partly account for the overexpression of CREB1 in GC. In conclusion, our results provide novel insight into the TF-miRNA regulatory network involved in GC metastasis. Targeting the GATA6/miR-520b/CREB1 axis may be an effective approach for GC treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression

Hao Liu, Danxiu Li, Lina Sun, Hongqiang Qin, Ahui Fan, Lingnan Meng, Ramona Graves-Deal, Sarah E. Glass, Jeffrey L. Franklin, Qi Liu, Jing Wang, Timothy J. Yeatman, Hao Guo, Hong Zong, Shuilin Jin, Zhiyu Chen, Ting Deng, Ying Fang, Cunxi Li, John Karijolich, James G. Patton, Xin Wang, Yongzhan Nie, Daiming Fan, Robert J. Coffey, Xiaodi Zhao, Yuanyuan Lu

Summary: The study reveals that MIR100HG serves as a positive regulator of EMT in CRC, sustaining cetuximab resistance and promoting invasion and metastasis. It interacts with hnRNPA2B1 to control Wnt signaling transcriptional activity via regulation of TCF7L2 mRNA stability, forming a feedback loop that may contribute to cetuximab resistance and metastasis in CRC.

MOLECULAR CANCER (2022)

Correction Cell Biology

GATA6 suppresses migration and metastasis by regulating the miR-520b/CREB1 axis in gastric cancer (vol 13, 243, 2022)

Hao Liu, Feng Du, Lina Sun, Qingfeng Wu, Jian Wu, Mingfu Tong, Xin Wang, Qi Wang, Tianyu Cao, Xiaoliang Gao, Jiayi Cao, Nan Wu, Yongzhan Nie, Daiming Fan, Yuanyuan Lu, Xiaodi Zhao

CELL DEATH & DISEASE (2022)

Article Oncology

eEF1A1 promotes colorectal cancer progression and predicts poor prognosis of patients

A-hui Fan, Xiaojuan Zhao, Hao Liu, Danxiu Li, Tongtong Guo, Jiehao Zhang, Lili Duan, Hao Cheng, Yongzhan Nie, Daiming Fan, Xiaodi Zhao, Yuanyuan Lu

Summary: This study found that elevated expression of eEF1A1 is correlated with poor prognosis in colorectal cancer (CRC). Inhibition of eEF1A1 can suppress CRC cell proliferation and induce cell cycle arrest. Analysis identified that mitogen-activated protein kinases (MAPKs) signaling pathway is enriched in the high-eEF1A1 expression group.

CANCER MEDICINE (2023)

Article Biochemistry & Molecular Biology

Wnt signaling modulator DKK4 inhibits colorectal cancer metastasis through an AKT/Wnt/?-catenin negative feedback pathway

Junrong Liang, Lina Sun, Yujun Li, Wanning Liu, Danxiu Li, Ping Chen, Xin Wang, Juan Hui, Jinchi Zhou, Hao Liu, Tianyu Cao, Maogui Pang, Meng Guo, Xin Wang, Xiaodi Zhao, Yuanyuan Lu

Summary: This study investigated the expression and function of DKK4 in colorectal cancer (CRC). The results showed that DKK4 was upregulated in CRC cell lines and tissues, and it inhibited cell metastasis by repressing the Wnt signaling pathway. Through experiments and analysis, the researchers also revealed the regulatory mechanism of DKK4 and its potential therapeutic application.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

Article Medicine, Research & Experimental

Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases

Yangsong He, Yanan Han, A-Hui Fan, Danxiu Li, Boda Wang, Kun Ji, Xin Wang, Xiaodi Zhao, Yuanyuan Lu

Summary: This study compares the expression profile of immune cells in liver metastases and primary tumors in colorectal cancer patients. The researchers found differences in the spatial distribution of immune cells between these two types of tumors, with more immunosuppressive cells present in liver metastases, particularly macrophages with a CD68(-)CD163(+) phenotype.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Correction Biochemistry & Molecular Biology

Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K (vol 11, 67, 2012)

Gui Ren, Qifei Tian, Yanxin An, Bin Feng, Yuanyuan Lu, Jie Liang, Kai Li, Yulong Shang, Yongzhan Nie, Xin Wang, Daiming Fan

MOLECULAR CANCER (2022)

Article Immunology

Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer

Yan Pan, Linbin Lu, Huan Liu, Di Chen, Ning Han, Ruirong Yao, Xinlin Wang, Xianchun Gao, Jun Yu, Ling Chen, Fenli Zhou, Guangjun Hao, Yuanyuan Lu, Mengbin Li, Guangbin He, Fei Kang, Zengshan Li, Yongqiang Tang, Jinsong Zhang, Lichun Wei, Yongzhan Nie

Summary: Trastuzumab-containing chemotherapy is the standard first-line treatment for advanced gastric cancer (GC) with HER2 positive. However, few studies have explored the effectiveness of anti-PD-1 therapy in overcoming resistance to trastuzumab plus chemotherapy in advanced Epstein-Barr Virus-associated gastric cancer (EBVaGC) with PD-L1 and HER2 positive. In this case presentation, a 45-year-old man with advanced EBVaGC presented with fatigue, dysphagia, and weight loss. He received trastuzumab plus chemotherapy as first-line treatment, followed by nivolumab monotherapy, total radical gastrectomy plus sequential radiotherapy, and postoperative immunotherapy. The patient achieved a durable clinical benefit with a PFS of 28 months.

FRONTIERS IN IMMUNOLOGY (2022)

Editorial Material Cell Biology

Editorial: The role of interplay between metabolism and chromosomes in tumorigenesis

Lutao Du, Yuanyuan Lu, Jiayi Wang

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Article Medicine, Research & Experimental

Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis

Jing Ma, Jianhui Li, Nan He, Meirui Qian, Yuanyuan Lu, Xin Wang, Kaichun Wu

Summary: This study aimed to characterize the phenotypes of CD8(+) T cells in tumor infiltrating lymphocytes (TILs) and peripheral blood lymphocytes (PBLs) in gastric cancer patients and establish a useful survival prediction model.

JOURNAL OF TRANSLATIONAL MEDICINE (2023)

Review Integrative & Complementary Medicine

Chinese integrated guideline on the management of gastric precancerous conditions and lesions

Ping Wang, Peng Li, Yingxuan Chen, Li Li, Yuanyuan Lu, Weixun Zhou, Liqun Bian, Beihua Zhang, Xiaolan Yin, Junxiang Li, Jie Chen, Shutian Zhang, Yongquan Shi, Xudong Tang

Summary: This guideline, created by 5 traditional Chinese medicine and Western medicine associations, provides specific key points and strategies for the diagnosis and treatment of gastric precancerous conditions and lesions, aiming to achieve effective secondary prevention of gastric cancer.

CHINESE MEDICINE (2022)

Article Biochemistry & Molecular Biology

Redox Dysregulation in the Tumor Microenvironment Contributes to Cancer Metastasis

Wanning Liu, Boda Wang, Mingzhen Zhou, Dan Liu, Fulin Chen, Xiaodi Zhao, Yuanyuan Lu

Summary: Redox dysregulation leads to ROS accumulation, causing oxidative stress and cellular damage. ROS play a dual role in cancer development and survival. Recent studies have shown that ROS impact the behavior of cancer cells and tumor-associated stromal cells in the TME, and these cells have developed complex systems to adapt to high ROS environments.

ANTIOXIDANTS & REDOX SIGNALING (2023)

Article Surgery

Impact of HER2 on prognosis and benefit from adjuvant chemotherapy in stage II/III gastric cancer patients: a multicenter observational study

Xianchun Gao, Lulu Zhao, Nannan Zhang, Weili Han, Kun Liu, Junya Yan, Ling Chen, Yan Pan, Renlong Li, Wenjiao Li, Haohao Zhang, Hongwei Li, Shibo Wang, Xiaoliang Gao, Penghui Niu, Wanqing Wang, Gang Ji, Qingchuan Zhao, Yuanyuan Lu, Zengshan Li, Lei Shang, Han Liang, Kaichun Wu, Jingyu Deng, Yingtai Chen, Yongzhan Nie

Summary: This multicenter cohort study involving 5622 consecutive stage II/III gastric cancer patients found that HER2 overexpression is associated with a lower 5-year overall survival in stage II patients but not in stage III patients. Further analysis revealed that stage II patients with high HER2 expression had a poorer response to chemotherapy. Prospective trials are needed to validate alternative HER2-targeted adjuvant therapies in stage II gastric cancer patients with high HER2 expression.

INTERNATIONAL JOURNAL OF SURGERY (2023)

Article Oncology

Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer

Xianchun Gao, Weili Han, Ling Chen, Hongwei Li, Fenli Zhou, Bin Bai, Junya Yan, Yong Guo, Kun Liu, Wenjiao Li, Renlong Li, Qiangqiang Yuan, Jiehao Zhang, Yuanyuan Lu, Xiaodi Zhao, Gang Ji, Mengbin Li, Qingchuan Zhao, Kaichun Wu, Zengshan Li, Yongzhan Nie

Summary: CDX2 expression is associated with prognosis and adjuvant chemotherapy benefits in stage II/III gastric cancer patients. CDX2-negative patients have a poorer prognosis without adjuvant chemotherapy, but their prognosis becomes similar to CDX2-positive patients when receiving postoperative chemotherapy. Therefore, active chemotherapy is more urgent for patients with negative CDX2 expression.

CANCER MEDICINE (2023)

Review Oncology

Regulatory role of exosomes in colorectal cancer progression and potential as biomarkers

Juan Hui, Mingzhen Zhou, Guangzhou An, Hui Zhang, Yuanyuan Lu, Xin Wang, Xiaodi Zhao

Summary: Colorectal cancer (CRC) poses a significant global health challenge, yet its progression mechanism remains poorly understood. Exosomes have been identified as playing a crucial role in CRC progression, attracting extensive research attention. In addition to their role as messengers between CRC cells, exosomes also contribute to CRC immunomodulation and immune function reshaping. As stable carriers of information and a developing liquid biopsy option, exosomes show promise as biomarkers for CRC diagnosis or treatment. This review explores the biogenesis and release of exosomes, current research on their role in immune regulation and metastasis of CRC, and their significance as potential biomarkers and immunotherapy targets in CRC.

CANCER BIOLOGY & MEDICINE (2023)

Article Medicine, Research & Experimental

A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer

Tianyu Cao, Yuanyuan Lu, Qi Wang, Hongqiang Qin, Hongwei Li, Hao Guo, Minghui Ge, Sarah E. Glass, Bhuminder Singh, Wenyao Zhang, Jiaqiang Dong, Feng Du, Airong Qian, Ye Tian, Xin Wang, Cunxi Li, Kaichun Wu, Daiming Fan, Yongzhan Nie, Robert J. Coffey, Xiaodi Zhao

Summary: De novo and acquired resistance are major impediments to cancer therapy. A study identified CGA as a prognostic biomarker and therapeutic target in chemoresistant gastric cancer (GC). High levels of CGA were found in chemoresistant GC cells and tissues, and elevated plasma CGA levels were correlated with reduced chemotherapy responsiveness and poor survival. CGA promoted survival and activated EGFR signaling in GC cells. Targeting CGA with anti-EGFR therapies or microRNAs restored chemotherapy sensitivity.

JOURNAL OF CLINICAL INVESTIGATION (2022)

No Data Available